Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BDD for multiple myeloma with acute renal failure
2005-003001-85Phase 2Completed
- Sponsor
- Austrian Forum Against Cancer
- Start
- Oct 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib, doxorubicin and dexamethasone in multiple myeloma (MM), sponsored by Austrian Forum Against Cancer. Primary endpoint: Reversal of renal failure. Started Oct 2005; status: completed.
02
Drugs
bortezomibdoxorubicindexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2005-003001-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003001-85.